AAV-Based Gene Therapy
AssigneeArthrogen B.V.
InventorsJonathan D. FINN, Margarita Jacoba Bernadetta Maria VERVOORDELDONK, Paul-Peter TAK
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of andeno-associated virus (AAV) based gene therapy, in particular to the use of a combination of recombinant AAV-transgene vectors with an immunosuppressant and/or empty-AAV capsids. The invention further provides a composition and a kit of parts based on this combination.
Claims16
A rAAV vector composition and an immunosuppressant for use in a treatment comprising gene therapy, wherein the treatment comprises the administration of the rAAV vector composition and the administration of the immunosuppressant to an individual, wherein the rAAV vector composition comprises a rAAV-transgene vector and an empty capsid in a ratio of empty capsid to rAAV-transgene vector of at least 1:1.
A rAAV vector composition, wherein the immunosuppressant is comprised within the rAAV vector composition.
A kit of parts comprising:
- a rAAV vector composition comprises a rAAV-transgene vector and an empty capsid in a ratio of empty capsid to rAAV-transgene vector of at least 1:1 and;
- an immunosuppressant.
Dependencies are inferred from the claim text.